Jump to content



Recommended Posts

This is a few years down the road, but very interesting.

Catalysts which cause cancer cells to ''commit suicide'' have been developed

in the laboratory by West Country scientists.

The research groups of Dr Claus Jacob, of Exeter University and Dr Nicholas

Gutowski at the Royal Devon and Exeter Hospital, with support from the

Peninsula Medical School, are investigating the anti-cancer effects of

biocatalysts that mimic the activity of the human selenium enzyme,

glutathione peroxidase. Their work opens up a very promising new direction

for anti-cancer research, but both stress that any potential treatment for

sufferers is still many years away.

Dr Jacob, of the University''s School of Biological and Chemical Sciences,

explained: ''The catalysts work by initiating reactions inside the cancer

cell that cause it to destroy itself. In effect, the cancer commits suicide.

One of the benefits of this approach is that the drugs target only the

diseased cells. The research opens up the possibility in the future of an

entirely new way of treating cancer that has two advantages over

conventional treatments:

1. The catalysts use the particular makeup of cancer cells for their

activity and thus do not work in healthy cells. This means they are far more

targeted than conventional drugs and could potentially avoid many of the

unpleasant side effects associated with chemotherapy and radiotherapy.

2. Catalysts are not consumed during their activity but are recycled over

and over again. This means that only minute quantities of biocatalyst are

needed to kill cancer cells making them highly efficient.

Dr Jacob said: ''Cancer therapy has long been based on highly toxic

substances that randomly kill healthy and sick cells alike. This new

approach might allow us to single out sick cells and kill them with a

catalytic efficiency far superior to conventional radiation or chemotherapy.

The experimental results obtained so far have been truly impressive but

further evaluation and clinical trials are required to develop this.''

The compounds have been developed and synthesised at the University''s

School of Biological and Chemical Sciences and tested in cancer cells at the

Royal Devon and Exeter Hospital. The work has been partially funded by the

Leverhulme Trust. An Exeter based company has already shown an interest in

the compounds and the new method. The most active compound tested so far is

a multifunctional catalyst that integrates a quinone with a chalcogen redox

system in one chemically simple molecule.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.